怀孕前或怀孕期间接受恩替卡韦或阿德福韦酯治疗的慢性乙

StephenW

J Matern Fetal Neonatal Med. 2020 Feb 4:1-5. doi: 10.1080/14767058.2020.1723540. [Epub ahead of print]
Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy.
Gao X1, Duan X1, Cai H2, Hu Y3, Liu M3, Kang K3, Zhou M3, Fu D3, Yi W3.
Author information
Abstract

Background: Entecavir (ETV) or adefovir dipivoxil (ADV) are not recommended during pregnancy because of embryotoxicity or teratogenicity found in animal studies; however, information on the safety of ETV or ADV in humans is limited.Aims: The aim of this study was to investigate the safety of ETV or ADV in women with chronic hepatitis B (CHB).Methods: We retrospectively enrolled 152 pregnant women with CHB who exposed to ETV or ADV in the first trimester of pregnancy. All the mothers were followed until postpartum 7 months. All newborns received immunoprophylaxis. The primary endpoint was the safety of mothers and infants. The secondary endpoint was the rate of mother-to-child transmission (MTCT) of hepatitis B virus (HBV).Results: The pregnant women were divided into two groups. Group 1 included 20 pregnant women who became unplanned pregnancy with ETV or ADV treatment. All of them switched to TDF before 7 weeks of gestation. There were 20 women with 20 pregnancies and 18 live births. Group 2 included 132 with TDF before conception. There were 132 women with 141 pregnancies and 125 live births. The abortion rate of Group 1 was not higher than that in Group 2 (10.0 versus 10.6%, p = 1.000). The birth defect rate in Group 1 did not statistically differ from Group 2 (5.6 versus 4.8%, p = 1.000). There were no significant differences of gestational complications between the two groups. The rate of MTCT of HBV is 0%.Conclusions: Among infants exposed to ETV or ADV before conception, ETV or ADV was not associated with a higher risk for adverse birth outcomes.
KEYWORDS:

Antiviral agents; chronic hepatitis B; infant; pregnancy; pregnancy complications

PMID:
    32019360
DOI:
    10.1080/14767058.2020.1723540

StephenW

J Matern胎儿新生儿医学。 2020年2月4日：1-5。 doi：10.1080 / 14767058.2020.1723540。 [Epub提前发行]
怀孕前或怀孕期间接受恩替卡韦或阿德福韦酯治疗的慢性乙型肝炎孕妇的妊娠结局。
高X1，段X1，蔡H2，胡Y3，刘M3，康K3，周M3，付D3，易W3。
作者信息
抽象

背景：由于动物研究发现胚胎毒性或致畸性，不建议在怀孕期间使用恩替卡韦（ETV）或阿德福韦酯（ADV）。目的：本研究的目的是调查慢性乙型肝炎（CHB）妇女中ETV或ADV的安全性。方法：我们回顾性研究了152例孕妇。怀孕前三个月接触过ETV或ADV的CHB。所有母亲均得到随访，直到产后7个月。所有新生儿均接受了免疫预防。主要终点是母亲和婴儿的安全。次要终点是乙型肝炎病毒（HBV）的母婴传播率。结果：孕妇分为两组。第一组包括20名孕妇，他们通过ETV或ADV治疗计划外怀孕。他们都在妊娠7周之前改用了TDF。有20名妇女怀孕20例，活产18例。第2组包括132名受孕前的TDF。有132名妇女怀孕141例，活产125例。第一组的流产率不高于第二组（10.0对10.6％，p = 1.000）。第1组的出生缺陷率与第2组无统计学差异（5.6比4.8％，p = 1.000）。两组之间的妊娠并发症没有显着差异。 HBV的MTCT发生率为0％。
关键字：

抗病毒药；慢性乙型肝炎婴儿;怀孕;妊娠并发症

PMID：
    32019360
DOI：
    10.1080 / 14767058.2020.1723540

deihai

男人吃恩替期间可能要孩子吗

StephenW

回复 deihai 的帖子

没有医学反对, 以上研究似乎表明对女的怀孕也很安全.

阿郎的故事

谢谢分享~感谢版主一如既往的坚持分享